In a $350 million deal with US based Eli Lily, Glenmark Pharmaceuticals has out-licensed GRC 6211 and a few other smaller molecules with potential to treat pain.
Glenmark has received an upfront payment of $45 million from Eli Lily and going forward the companies will share the benefits from the sales when it hits the market in 2012.